All In Biotech

Drug Trial Radar · NCT07593404

Evaluation of a Novel Ocular Lubricating Eye Drop

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

May 28, 2026

Primary completion

Nov 2026

Study completion Feb 2027

Sponsor

Sponsor type
Industry
Collaborators
University of Waterloo
First posted
May 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this 2-part study is to assess the safety and tolerability of the new ocular lubricating drop ABR2 during short-term use in subjects for the temporary relief of ocular discomfort due to dryness of the eye. In Part 1, participant will receive 1 drop of ABR2 in one eye and through assessments over a 1-hour period. In Part 2, participant will use 1 drop of ABR2 at least two times a day for 28-day period (may use up to 4 times a day as needed) This is a single arm, open label study with no placebo or comparative arm.

Conditions

  • Dry Eye Syndrome (DES)

Interventions

  • Part 2 ABR2 At least twice a day for 28 daysDrug

    Use ABR2 at least BID, up to QID for 28 days

  • Part 1: ABR2 single dose in one eyeDrug

    Receive a single dose in one eye only

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse EventsTime frame: At the end of Part 1: 60 minutes after single drop monocular instillation and At the end of Part 2 (after 28 days of bilateral use)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Ocular Research & Education, School of Optometry & Vision Science, University of Waterloo

    Waterloo, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.